PVCT Provectus Biopharmaceuticals - Should Mgt update the Shareholders on the current direction of the company? - PVCT Provectus Biopharmaceuticals - InvestorVillage


PVCT Provectus Biopharmaceuticals
This is a semi-private group. You are free to browse messages, but you must be a member of this group to post messages. Join This Group

Group: PVCT Provectus Biopharmaceuticals   /  Message Board  /  Read Message

 
 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  6701 of 6830  at  9/25/2022 3:43:52 PM  by

Take_The_Canolis

The following message was updated on 9/25/2022 5:16:02 PM.

Should Mgt update the Shareholders on the current direction of the company?

 
The AM was just 3 months ago, so it appears that Mgt must have known that it was headed toward the BascomPalmer licensing arrangement (PDAT).  Additionally, the recent posting of info related to PDT/RB usage in Breast Cancer cases seems to confirm that PDT/RB is an approach with much potential.  
 
So, how does PDAT and PDT  portend for the companies main product, PV-10?
 
Is it a brand new road opening...or is it serious competition?   
 
Mgt has worked hard to patent many aspects of PV-10, but I don't know if unprocessed RB is a serious threat to PV-10.
 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 0  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
6702 Re: Should Mgt update the Shareholders on the current direction of the company? Atlas 2 9/25/2022 5:03:33 PM




Financial Market Data provided by
.
Loading...